Sanofi announced new findings from a real-world observational study showing a significantly lower risk of hypoglycemia in patients with type 2 diabetes using basal insulin who switched to Toujeo (insulin glargine) when compared to other basal insulins. 

DELIVER 1 (n=881) was an earlier real-world observational study that evaluated the change in HbA1c and incidence of hypoglycemia based on electronic medical data up to six months after switching to Toujeo from another basal insulin. 

DELIVER 2 evaluated data from the Predictive Health Intelligence Environment (PHIE) database of real-world electronic medical records for 1,894 patients in two matched cohorts. The study assessed HbA1c reduction from baseline, HbA1c goal attainment (<7%  and <8%), incidence of hypoglycemia, and hypoglycemic events related to inpatient and emergency department (ED) visits with Toujeo vs. other basal insulins (insulin glargine, insulin detemir, and insulin degludec).  

Related Articles

After six months, patients who switched to Toujeo had 33% less hypoglycemic events (event rate per 100 patient-months: 7.98 vs. 5.32; P<0.01) compared to those who switched to other basal insulins without compromising blood sugar control (difference –2.67 events per 100 patient-months; P<0.01). Patients who switched to Toujeo also had a 48% reduction in hypoglycemic events related to inpatient or emergency department encounters (3.82 vs. 1.97; P<0.01) compared to other basal insulins.

The Company is also conducting a clinical program made up of three randomized, prospective real-life clinical studies (n>4,500) with Toujeo to complement the observational studies in routine practice: ACHIEVE CONTROL, REACH CONTROL, and REGAIN CONTROL.

Toujeo, a long-acting insulin, is indicated to control blood sugar in adults with diabetes mellitus. It contains three times as much insulin in 1mL as standard insulin. Toujeo is available as 300 Units/mL insulin glargine in 1.5mL SoloStar disposable prefilled pens. 

For more information call or visit